Haematology

EHA 2024

Meet the Expert: Prof. C. Ola Landgren discusses MRD as a key endpoint in haematological cancer trials

Expert

Prof. C. Ola Landgren, University of Miami, FL, USA

Conference

EHA 2024

10 July 2024 16:53

EHA 2024 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

EHA 2024

2 July 2024 21:58

Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for MF?

Presented By

Dr Raajit Rampal, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, MANIFEST-2

Conference

EHA 2024

Type

News article

20 June 2024 11:08

First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL

Presented By

Prof. Paolo Ghia, University Vita-Salute San Raffaele, Italy

Trial

Phase 3, SEQUOIA

Conference

EHA 2024

Type

News article

20 June 2024 11:06

Promising results for novel CAR T-cell therapy in MM in phase 1 trial

Presented By

Dr Binod Dhakal, Medical College of Wisconsin, WI, USA

Trial

Phase 1

Conference

EHA 2024

Type

News article

20 June 2024 10:59

ESLIM-01: Sovleplenib delivers durable responses and QoL improvements in primary ITP

Presented By

Dr Renchi Yang, Chinese Academy of Medical Sciences, China

Trial

Phase 3, ESLIM-01

Conference

EHA 2024

Type

News article

20 June 2024 10:58

AUGMENT-101: revumenib trial in KMT2Ar leukaemia stopped early for efficacy

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

EHA 2024

Type

News article

20 June 2024 10:57

Clinically meaningful outcomes for mosunetuzumab across FL subgroups

Presented By

Dr Sarit Assouline, Jewish General Hospital, Canada

Trial

Phase 2

Conference

EHA 2024

Type

News article

20 June 2024 10:55

Excellent phase 3 results for asciminib in CML

Presented By

Prof. Andreas Hochhaus, Jena University Hospital, Germany

Trial

Phase 3, ASC4FIRST

Conference

EHA 2024

Type

News article

19 June 2024 09:55

EPCORETM CLL-1: promising data for epcoritamab in high-risk Richter’s transformation

Presented By

Prof. Arnon Kater, University of Amsterdam, the Netherlands

Trial

Phase 1/2, EPCORE CLL-1

Conference

EHA 2024

Type

News article

19 June 2024 09:54

ENERGIZE: mitapivat meets primary efficacy endpoint in thalassaemia

Presented By

Prof. Ali Taher, American University of Beirut, Lebanon

Trial

Phase 3, ENERGIZE

Conference

EHA 2024

Type

News article

19 June 2024 09:52

Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, IMROZ

Conference

EHA 2024

Type

News article

19 June 2024 09:50

RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease

Presented By

Dr Rabi Hanna, Cleveland Clinic, OH, USA

Trial

Phase 1/2, RUBY

Conference

EHA 2024

Type

News article

19 June 2024 09:48

Navitoclax plus ruxolitinib leads to spleen volume reductions in MF in TRANSFORM-1 trial

Presented By

Prof. Naveen Pemmaraju, MD Anderson Cancer Center, TX, USA

Trial

Phase 3, TRANSFORM-1

Conference

EHA 2024

Type

News article

19 June 2024 09:47

DREAMM 8: belantamab mafodotin offers hope for patients with RR MM

Presented By

Prof. Meletious Dimopoulos, University of Athens, Greece

Trial

Phase 3, DREAMM 8

Conference

EHA 2024

Type

News article

18 June 2024 10:35

High survival rates following atezolizumab consolidation therapy in DLBCL

Presented By

Dr Marcel Nijland, University Medical Center Groningen, the Netherlands

Trial

Phase 2, HOVON 151

Conference

EHA 2024

Type

News article

18 June 2024 10:33

APOLLO: ATRA plus ATO meets expectations in high-risk APL

Presented By

Dr Uwe Platzbecker, Leipzig University Hospital, Germany

Trial

Phase 3, APOLLO

Conference

EHA 2024

Type

News article

18 June 2024 10:32

ECHO: Can we expect a novel standard of care in newly diagnosed MCL?

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, ECHO

Conference

EHA 2024

Type

News article

18 June 2024 10:30

Can golcadomide plus R-CHOP become the first-line standard of care in DLBCL?

Presented By

Dr Marc Hoffman, The University of Kansas Cancer Center, KS, USA

Trial

Phase 1, CC-220-DLBCL-001

Conference

EHA 2024

Type

News article

18 June 2024 10:29

FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML

Presented By

Dr Wei-Ying Jen, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

EHA 2024

Type

News article

18 June 2024 10:26

ASH 2023

Letter from the Editor

Editor

Prof. Gert Ossenkoppele, Amsterdam UMC, the Netherlands

Conference

ASH 2023

7 February 2024 15:14

FLT3-ITD-specific MRD assessment useful for clinical management of AML

Presented By

Prof. Alexander Perl, University of Pennsylvania, PA, USA

Trial

Phase 3, QuANTUM-First

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:05

MRD status rather than FLT3-ITD co-mutation is linked to the benefit of CR1-allo in NPM1-mutated AML

Presented By

Dr Jad Othman, Royal North Shore Hospital, Australia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Promising results for quizartinib, venetoclax, and decitabine in FLT3-ITD mutated AML

Presented By

Dr Musa Yilmaz, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

AUGMENT-101: Excellent results for revumenib in R/R KMT2Ar leukaemia

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Blinatumomab reduces toxicity in the consolidation phase in paediatric high-risk B-cell ALL

Presented By

Prof. Martin Schrappe, Hong Kong College of Paediatricians, China

Trial

Phase 3, AIEOP-BFM ALL 2017

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:02

Promising results for olverembatinib in combination with venetoclax for Ph+ ALL

Presented By

Dr Xiaoyuan Gong, Chinese Academy of Medical Sciences, China

Trial

Phase 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:02

Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants

Presented By

Dr Moritz Fürstenau, University of Cologne, Germany

Trial

Phase 2, CLL2-BAAG

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:01

Is allogeneic stem cell transplantation a solid option in R/R LBCL or R/R T-cell lymphoma?

Presented By

Prof. Bertram Glass, Helios Klinikum Berlin-Buch, Germany

Trial

Phase 2, ASTRAL

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Encouraging results for the addition of acalabrutinib to lenalidomide and rituximab in follicular lymphoma

Presented By

Dr Paolo Strati, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Can ibrutinib ameliorate outcomes in R/R ABC-DLBCL undergoing autoSCT?

Presented By

Dr Charalambos Andreadis, University of California San Francisco, USA

Trial

Phase 3, A051301/BMT-CTN 1201

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

Primary phase 2 efficacy and safety results of M-Pola in relapsed/refractory LBCL

Presented By

Dr Elizabeth Budde, City of Hope National Medical Center, CA, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

SYMPATICO: Ibrutinib plus venetoclax boosts PFS in R/R mantle cell lymphoma

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, SYMPATICO

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

KdD outperforms Kd in R/R MM also in participants with poor renal function

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, CANDOR

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:58

IsKia: Novel treatment regimen for MM delivers high MRD-negativity rates

Presented By

Prof. Francesca Gay, University of Torino, Italy

Trial

Phase 3, IsKia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

TRANSFORM-1: High spleen volume reduction rates for navitoclax plus ruxolitinib in myelofibrosis

Presented By

Prof. Naveen Pemmaraju, MD Anderson Cancer Center, TX, USA

Trial

Phase 3, TRANSFORM-1

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

Momelotinib beats controls regarding transfusion outcomes in myelofibrosis

Presented By

Prof. Ruben Mesa, Wake Forest Baptist Comprehensive Cancer Center, NC, USA

Trial

Phase 3, Simplify-1, MOMENTUM

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

DALIAH: Peginterferon-α head-to-head against hydroxyurea in MPN

Presented By

Dr Trine Knudsen, University Hospital Odense, Denmark

Trial

Phase 3, DALIAH

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

Long-term efficacy and safety of iptacopan in PNH with anaemia

Presented By

Prof. Antonio Risitano, University of Naples, Italy

Trial

Phase 3, APPLY-PNH

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:56

ADVANCE IV: Swift responses on efgartigimod in ITP

Presented By

Prof. Catherine Broome, Georgetown University, DC, USA

Trial

Phase 3, ADVANCE IV

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:56

Favourable QoL and bleeding outcomes for rilzabrutinib in ITP

Presented By

Prof. Michael Tarantino, University of Illinois, IL, USA

Trial

Phase 1/2, LUNA 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:55

Novel risk assessment model acts on increasing hospital-acquired venous thromboembolism rates among children

Presented By

Dr Julie Jaffray, Rady Children’s Hospital-San Diego, CA, USA

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:55

Axatilimab may present a new therapeutic strategy in chronic GvHD

Presented By

Prof. Daniel Wolff, University Hospital Regensburg, Germany

Trial

Phase 2, AGAVE-201

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:54

Pomalidomide may become the first approved therapy for hereditary haemorrhagic telangiectasia

Presented By

Prof. Keith McCrae, Cleveland Clinic, OH, USA

Trial

Phase 2, PATH-HHT

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:54

Ancestry-specific study into CH delivers new leads

Presented By

Dr Sean Wen, University of Cambridge, UK

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:54

Novel standard-of-care in newly diagnosed MM

Presented By

Prof. Pieter Sonneveld, Erasmus MC, the Netherlands

Trial

Phase 3, Perseus

Conference

ASH 2023

Type

Peer-reviewed article

6 February 2024 16:34

Interview: Sandwich treatment model shows promise for mantle cell lymphoma

Expert

Dr Eliza Hawkes, Olivia Newton-John Cancer Wellness & Research Centre, Australia

Trial

Phase 2, WAMM

Conference

ASH 2023

4 January 2024 14:30

ASH 2023 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

ASH 2023

4 January 2024 10:55

Meet the Trialist: Prof. Jeff Sharman on ELEVATE-TN

Expert

Prof. Jeff Sharman , The US Oncology Network and Willamette Valley Cancer Institute, Oregon, USA

Trial

Phase 3, ELEVATE-TN

Conference

ASH 2023

18 December 2023 18:14

EHA 2023

Letter from the Editor

Presented By

Prof. Gert Ossenkoppele, Amsterdam UMC, the Netherlands

Conference

EHA 2023

2 August 2023 18:13

COMMANDS trial: A paradigm shift in LR-MDS-associated anaemia

Presented By

Dr Matteo Della Porta, Humanitas Cancer Centre Milan, Italy

Trial

Phase 3, COMMANDS

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:39

REVIVE: Rusfertide meets the primary endpoint in PV

Presented By

Dr Marina Kremyanskaya, Mount Sinai, New York, USA

Trial

Phase 2, REVIVE

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:34

Mapping healthy HPSC variations to diagnose haematopoietic abnormalities

Presented By

Dr Nili Furer, Weizmann Institute of Science, Israel

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:28

High risk of death for individuals with C282Y/C282Y hereditary haemochromatosis and diabetes

Presented By

Dr Mathis Mottelson, Copenhagen University Hospital, Denmark

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:05

QuANTUM-First: Updated results on quizartinib in AML with FLT3-ITD

Presented By

Dr Richard Schlenk, University of Heidelberg, Germany

Trial

Phase 3, QuANTUM-First

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:54

Promising data for ziftomenib in relapsed/refractory NPM1-mutated AML

Presented By

Dr Amir Fathi, Massachusetts General Hospital, Massachusetts, USA

Trial

Phase 1/2, KOMET-001

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:51

MRD-positive patients with FLT3-ITD AML may benefit from post-transplant gilteritinib

Presented By

Dr Mark Levis, Johns Hopkins Hospital, Maryland, USA

Trial

MORPHO

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:45

Deep responses with asciminib in CML-CP  

Presented By

Prof. Timothy Hughes, University of Adelaide, Australia

Trial

Phase 3, ASCEMBL

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:41

QUIWI: First results suggest a clinical benefit of quizartinib in AML

Presented By

Dr Pau Montesinos, University of Valencia, Spain

Trial

Phase 2, QUIWI

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:38

Investigational agent OMS906 performs well in PNH

Presented By

Dr Jens Panse, University of Aachen, Germany

Trial

Phase 1

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:32

Robust platelet responses with cevidoplenib in ITP

Presented By

Dr Jun-Ho Jang, Samung Medical Center, South Korea

Trial

Phase 2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:23

Radiotherapy or not in patients with PMBCL after immunochemotherapy?

Presented By

Dr Maurizio Martelli, University Sapienza Roma, Italy

Trial

IELSG37

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:16

Durable responses for loncastuximab tesirine in relapsed/refractory DLBCL

Presented By

Dr Paolo Caimi, Cleveland Clinic, Ohio, USA

Trial

Phase 2, LOTIS-2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:12

Zandelisib promising in relapsed/refractory indolent B-cell NHL

Presented By

Dr Takahiro Kumode, Kindai University, Japan

Trial

Phase 2, MIRAGE

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:05

Promising data for epcoritamab plus R-CHOP in untreated DLBCL

Presented By

Dr Michael Clausen, Lillebaelt Hospital, Denmark

Trial

Phase 1/2, EPCORETM NHL-2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:43

Can we combine teclistamab and nirogacestat for the treatment of RRMM?

Presented By

Dr Jeffrey Matous, Colorado Blood Cancer Institute, Colorado, USA

Trial

Phase 1, MajesTEC-2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:21

Encouraging results for low-dose belantamab mafodotin plus nirogacestat in patients with RRMM

Presented By

Prof. Sebastian Grosicki, Medical University of Silesia, Poland

Trial

Phase 1/2, DREAMM 5

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:15

CARTITUDE-4: Cilta-cel meets expectations in lenalidomide-refractory MM

Presented By

Dr Hermann Einsele, University of Würzburg, Germany

Trial

Phase 3, CARTITUDE-4

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:08

EHA 2023 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

EHA 2023

28 June 2023 07:19

EBMT 2023

Long-term success for CD19 CAR T-cell therapy in CLL

Presented By

Dr Emily Liang, University of Washington, WA, USA

Trial

Phase 2

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:31

Can molecular data improve prognostication in MDS patients undergoing HSCT?

Presented By

Dr Carmelo Gurnari, Cleveland Clinic, OH, USA & Tor Vergata University, Italy

Conference

EMBT 2023

Type

Peer-reviewed article

15 June 2023 17:27

Next-generation cell therapies for cancer: CAR-NK cells

Presented By

Dr Katy Rezvani, MD Anderson Cancer Center, TX, USA

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:20

Novel drugs and strategies around ASCT for Hodgkin lymphoma

Presented By

Dr Anna Sureda, Catalan Institute of Oncology, Spain

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:15

Thalassaemia: Advances in conventional transplantation and gene therapy

Presented By

Prof. Josu de la Fuente, Imperial College London, UK

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:06

New options to treat steroid-refractory chronic GvHD

Presented By

Prof. Mohamad Mohty, Sorbonne University, France

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 16:59

New developments in steroid-refractory acute GvHD

Presented By

Prof. Ronjon Chakraverty, University of Oxford, UK

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 16:54

Ide-cel superior to standard therapies in triple-class exposed RRMM

Presented By

Dr Paula Rodríguez-Otero, Clinica Universidad de Navarra, Spain

Trial

Phase 3, KarMMa-3

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 16:48

Letter from the Editor

Editor

Prof. Gert Ossenkoppele, Amsterdam UMC, the Netherlands

Conference

EBMT 2023

15 June 2023 13:27

ASCT or CAR T cell as first-line therapy for MM?

Presented By

Prof. Salomon Manier, Lille University Hospital, France

Trial

Phase 3, CARTITUDE-6

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:23

DETERMINATION: Does one size fit all in multiple myeloma?

Presented By

Dr Hani Hassoun, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, DETERMINATION

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:14

Quizartinib plus chemotherapy improves OS in patients with AML undergoing ASCT

Presented By

Prof. Radovan Vrhovac, University Hospital Centre Zagreb, Croatia

Trial

Phase 3, QuANTUM-First

Conference

EMBT 2023

Type

Peer-reviewed article

14 June 2023 20:07

Blinatumomab may improve outcomes in patients with B-cell ALL undergoing ASCT

Presented By

Dr Ayman Sayyed, University of Toronto, Canada

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:02

Is ASCT a reasonable option in patients with invasive aspergillosis?

Presented By

Prof. Olaf Penack, Charité University Hospital of Berlin, Germany

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:55

Tacrolimus versus cyclosporine A in AML

Presented By

Dr Gesine Bug, Goethe University Frankfurt, Germany

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:48

Promising novel target identified for AML

Presented By

Prof. Edmund Waller, Emory University, GA, USA

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:42

EBMT 2023 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

EBMT 2023

14 May 2023 20:09

CAR T cells rise to the front in multiple myeloma

Expert

Dr Sergio Giralt, Memorial Sloan Kettering Cancer Center, USA

Trial

Phase 3, KarMMa-3

17 April 2023 12:45

ASH 2022

Letter from the Editor

Editor

Prof. Gert Ossenkoppele, Amsterdam UMC, the Netherlands

Conference

ASH 2022

20 February 2023 13:27

C1 inhibitor deficiency linked to thrombosis

Presented By

Dr Steven Grover, University of North Carolina, NC, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:18

Durable responses to gene therapy in haemophilia A

Presented By

Prof. Stacy Croteau, Harvard Medical School, MA, USA

Trial

Phase 1/2, SPK-8011

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:16

Long-term benefits from beti-cel in transfusion-dependent β-thalassaemia

Presented By

Prof. Mark Walters; Prof. Franco Locatelli

Trial

LTF-303

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:14

Neutrodiet: non-restricted diet is the preferred option after SCT

Presented By

Prof. Federico Stella, Università degli Studi di Milano, Italy

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:11

Iptacopan offers solution for patients with PNH and residual anaemia after standard-of-care 

Presented By

Prof. Régis de Latour, Saint-Louis Hospital, France

Trial

Phase 3, Apply-PNH

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:09

Novel therapy may replace standard-of-care prophylaxis for GVHD

Presented By

Prof. Shernan Holtan, University of Minnesota, MN, USA

Trial

Phase 3, BMT CTN 1703

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:05

LMWH does not result in higher live birth rates in women with inherited thrombophilia 

Presented By

Prof. Saskia Middeldorp, Radboud UMC, the Netherlands

Trial

ALIFE2

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:01

Efgartigimod successful in immune thrombocytopenia 

Presented By

Prof. Catherine Broome, Georgetown University, Washington DC, USA

Trial

Phase 3, ADVANCE

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:57

Long-term risk for haematologic disease in persistent, isolated mild thrombocytopenia

Presented By

Dr Nardeen Ayad, Massachusetts General Hospital, MA, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:50

INCA033989: novel investigational agent for CALR-mutated MPN

Presented By

Dr Edimara Reis, Incyte Corporation, DE, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:47

Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN

Presented By

Dr Nabih Maslah, Université Paris Cité, France

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:43

Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma 

Presented By

Prof. Martin Dreyling, University Hospital Munich, Germany

Trial

Phase 3, Triangle

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:39

High-dose chemotherapy plus ASCT superior to standard immuno-chemotherapy in primary CNS lymphoma 

Presented By

Prof. Gerald Illerhaus, Klinikum Stuttgart, Germany

Trial

Phase 3, MATRix/IELSG43

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:37

Odronextamab has considerable anti-tumour effects in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Presented By

Prof. Won-Seog Kim, Samsung Medical Center, South Korea

Trial

Phase 2, ELM-2 trial

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:30

Excellent results for AFM13-complexed NK cells in CD30-positive lymphoma

Presented By

Dr Yago Nieto, University of Texas, TX, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:27

CAR-Hematotox score predicts toxicity, infections, and clinical outcomes in MCL 

Presented By

Dr Kai Rejeski, LMU Munich, Germany

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:23

Talquetamab further investigated in heavily pre-treated MM after promising phase 2 data 

Presented By

Prof. Ajai Chari, Mount Sinai School of Medicine, NY, USA

Trial

Phase 1/2, MonumenTAL-1

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:19

Promising results of elranatamab for MM in phase 2 MagnetisMM-3 trial 

Presented By

Prof. Nizar Bahlis, University of Calgary, Canada

Trial

Phase 2, MagnetisMM-3

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:09

Deep and durable responses for quadruple therapy in smouldering MM 

Presented By

Prof. Shaji Kumar, Mayo Clinic, MN, USA

Trial

Phase 2, ASCENT

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:04

Ultra-sensitive MRD assessment in MM with BloodFlow

Presented By

Dr Laura Notarfranchi, University of Parma, Italy

Trial

Phase 3, GEM2014MAIN

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:55

CAR-Hematotox score proves useful in relapsed/refractory MM

Presented By

Dr Kai Rejeski, LMU Munich, Germany

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:52

Head-to-head: VMP versus Rd in transplant-ineligible MM

Presented By

Dr Sara Bringhen, Università degli Studi di Torino, Italy

Trial

Phase 4, REAL-MM

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:47

Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL

Presented By

Prof. Jennifer Brown, Dana Farber Cancer Institute, MA, USA

Trial

Phase 3, ALPINE

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:40

Ibrutinib plus venetoclax displays long-term benefits in CLL 

Presented By

Prof. John Allan, Weill Cornell Medicine, NY, USA

Trial

Phase 2, CAPTIVATE

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:28

Excellent results for triplet regimen in FLT3-mutated AML 

Presented By

Prof. Nicholas Short, University of Texas, TX, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:25

MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML 

Presented By

Mr Jad Othman, Guy’s and St Thomas’ NHS Foundation Trust, UK

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:20

Promising results for triplet therapy with magrolimab in AML

Presented By

Prof. Naval Daver, Anderson Cancer Center, TX, USA

Trial

Phase 3, ENHANCE-3

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:17

Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML? 

Presented By

Prof. Matthias Stelljes, University of Muenster, Germany

Trial

Phase 3, EATL3-ASAP

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:13

Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL 

Presented By

Prof. Mark Litzow, Mayo Clinic, MN, USA

Trial

Phase 3, ECOG-ACRIN-E1910 NCTN

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:07

High-dose methotrexate or standard interim maintenance in young patients with ALL? 

Presented By

Ms Amy Kirkwood, University College London, UK

Trial

UKALL 2011

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:01

ASH 2022 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

ASH 2022

5 January 2023 02:23

EHA 2022

ASH 2021 Focus on CAR T-Cell Therapy

Welcome to our Focus Edition on CAR T-cell therapy news

Conference

ASH 2021

3 March 2022 23:38

ASH 2021 Focus on CAR T-Cell Therapy Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASH 2021

3 March 2022 23:28

Most re-hospitalisations within first month from CAR T-cell infusion

Expert

Dr Kelly Kenzik, Institute for Cancer Outcomes and Survivorship, University of Alabama, USA

Conference

ASH 2021

Type

News article

4 February 2022 11:36

CD22-directed CAR T-cell therapy safe and well-tolerated in R/R LBCL

Expert

Dr Matthew J. Frank, Stanford University School of Medicine, USA

Conference

ASH 2021

Type

News article

4 February 2022 11:30

High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma

Expert

Dr Sattva S. Neelapu, MD Anderson Cancer Center, Houston, USA

Trial

ZUMA-12

Conference

ASH 2021

Type

News article

4 February 2022 11:25

Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL

Expert

Dr Grzegorz Nowakowski, Mayo Clinic, Rochester, USA

Trial

Cohort study, RE-MIND2

Conference

ASH 2021

Type

News article

4 February 2022 11:08

Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma

Expert

Dr Manali Kamdar, University of Colorado Cancer Center, Denver, USA

Trial

Phase 3, TRANSFORM

Conference

ASH 2021

Type

News article

4 February 2022 10:28

CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL

Expert

Dr Geoffrey Shouse, City of Hope Comprehensive Cancer Center, USA

Conference

ASH 2021

Type

News article

4 February 2022 10:20

Axi-cel more effective but tisa-cel less toxic in large B-cell lymphoma

Expert

Dr Emmanuel Bachy, Hospices Civils de Lyon, France

Trial

JULIET, ZUMA-1

Conference

ASH 2021

Type

News article

4 February 2022 10:15

Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma

Expert

Dr Frederick Locke, Moffitt Cancer Cancer, Tampa, Florida, USA

Trial

Phase 3, ZUMA-7

Conference

ASH 2021

Type

News article

4 February 2022 10:10

Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL

Expert

Dr Michael R. Bishop, David and Etta Jonas Center for Cellular Therapy, University of Chicago, USA

Trial

Phase 3, BELINDA

Conference

ASH 2021

Type

News article

4 February 2022 10:03

Improved QoL with axi-cel versus standard-of-care in R/R LBCL

Expert

Dr Mahmoud Elsawy, Dalhousie University, Halifax, USA

Trial

Phase 3, ZUMA-7

Conference

ASH 2021

Type

News article

4 February 2022 09:48

ASH 2021

Letter from the Editor

Editor

Prof. Gert Ossenkoppele, Amsterdam UMC, the Netherlands

Conference

ASH 2021

4 February 2022 12:19

New Interfant protocol includes blinatumomab for KMT2A-r ALL

Presented By

Dr Inge van der Sluis, Princess Máxima Center for Pediatric Oncology, the Netherlands

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 12:00

Persistent disparities in ALL health outcomes

Presented By

Dr Sumit Gupta, University of Toronto, Canada

Trial

COG ALL

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:59

EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL

Presented By

Prof. Patrice Chevallier, Nantes University Hospital, France

Trial

Phase 2, EWALL-INO

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:57

UKALL 2003: Therapy de-escalation safe in low-risk MRD patients with ALL

Presented By

Dr Sujith Samarasinghe, Great Ormond Street Hospital, UK

Trial

UKALL 2003

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:55

AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML

Presented By

Dr Hartmut Döhner, Universitätsklinikum Ulm, Germany

Trial

Phase 2, AMLSG 16-10

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:53

Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients

Presented By

Dr Justin Grenet, Weill Cornell Medical Center, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:51

Promising frontline triplet regimen for TP53-mutated AML

Presented By

Dr Naval Daver, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:49

Encouraging results of novel triplet combination for AML

Presented By

Dr Patrick Reville, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:48

Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen

Presented By

Dr Musa Yilmaz, MD Anderson Cancer Center, TX, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:46

Benefits of eprenetapopt plus azacitidine for TP53-mutant MDS and oligoblastic AML

Presented By

Dr David Sallman, H. Lee Moffitt Cancer Center, FL, USA

Trial

Phase 2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:44

Improved risk stratification in MDS via gene-based scoring system

Presented By

Dr Elsa Bernard, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:43

CAPTIVATE: Ibrutinib plus venetoclax shows ongoing efficacy in CLL

Presented By

Dr Paolo Ghia, Università Vita-Salute San Raffaele, Italy

Trial

Phase 2, CAPTIVATE

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:41

SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naïve CLL/SLL

Presented By

Prof. Constantine Tam, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, SEQUOIA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:39

Investigational therapies superior to standard-of-care in double-exposed CLL

Presented By

Dr Meghan Thompson, Memorial Sloan Cancer Center, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:36

GRIFFIN: Sustained responses of daratumumab plus RVd in MM

Presented By

Dr Jacob Laubach, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 2, GRIFFIN

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:30

MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM

Presented By

Prof. Philippe Moreau, University Hospital of Nantes, France

Trial

Phase 1/2, MajesTEC-1

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:26

iStopMM: Smouldering MM highly prevalent in general population

Presented By

Dr Sigrún Thorsteinsdóttir, University of Iceland, Iceland

Trial

iStopMM

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:25

Mechanisms of D-KRd treatment failure in MM identified

Presented By

Dr Eileen Boyle, NYU Langone Health, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:22

TRIMM-2: Favourable results of talquetamab plus daratumumab for MM

Presented By

Dr Ajai Chari, Mount Sinai School of Medicine, NY, USA

Trial

Phase 1, TRIMM-2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:16

Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma

Presented By

Dr Michael Bishop, University of Chicago, IL, USA

Trial

Phase 3, BELINDA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:11

Axi-cel improved event-free survival in R/R DLBCL

Presented By

Dr Frederick Locke, Moffitt Cancer Cancer, FL, USA

Trial

Phase 3, ZUMA-7

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:09

Axi-cel more effective but tisa-cel less toxic in DLBCL

Presented By

Dr Emmanuel Bachy, Hospices Civils de Lyon, France

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:01

POLARIX: Novel regimen superior to R-CHOP in DLBCL

Presented By

Prof. Hervé Tilly, University of Rouen, France

Trial

Phase 3, POLARIX

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:56

Novel non-invasive biomarker ctDNA shows value in CNS lymphoma

Presented By

Dr Jurik Mutter, University Medical Center Freiburg, Germany

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:53

Mechanisms behind TP53 mutations revealed in myeloproliferative neoplasms

Presented By

Dr Alba Rodriguez-Meira, University of Oxford, UK

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:51

JAK2V617F variant allele frequency prognostic of venous events in polycythaemia vera

Presented By

Dr Giuseppe Loscocco, University of Florence, Italy

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:51

Promising results of tacrolimus plus dexamethasone for ITP

Presented By

Dr Zhuo-Yu An, Peking University People’s Hospital, China

Trial

Phase 2, TARGET 020

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:50

Sustained remission after TPO-RA discontinuation in chronic ITP

Presented By

Prof. Matthieu Mahevas, Hôpital Henri-Mondor, France

Trial

STOPAGO

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:50

Fitusiran meets primary endpoint in ATLAS-A/B trial

Presented By

Dr Alok Srivastava, Christian Medical College Vellore, India

Trial

Phase 3, ATLAS-A/B

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:50

ATLAS-INH: Impressive results of fitusiran for haemophilia with inhibitors

Presented By

Dr Guy Young, University of Southern California, CA, USA

Trial

Phase 3, ATLAS-INH

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:50

rFVIIIFc establishes rapid tolerisation in haemophilia A with inhibitors

Presented By

Dr Lynn Malec, Versiti Blood Research Institute, WI, USA

Trial

verITI-8

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:50

Reduced risk of Alzheimer’s disease in CHIP carriers

Presented By

Dr Hind Bouzid, Stanford University, CA, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:49

Lifelong patterns of clonal haematopoiesis revealed

Presented By

Dr Margarete Fabre, University of Cambridge, UK

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:49

ASH 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASH 2021

4 January 2022 08:00

EHA 2021

Letter from the Editor

Editor

Prof. Gert Ossenkoppele, Amsterdam UMC, the Netherlands

Conference

EHA 2021

5 August 2021 16:10

Luspatercept improved anaemia in patients with non-transfusion-dependent β-thalassaemia

Presented By

Prof. Ali Taher, American University of Beirut Medical Center, Lebanon

Trial

Phase 2, BEYOND

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:43

Personalising treatment for sickle cell disease

Presented By

Dr Erfan Nur, Amsterdam University Medical Center, the Netherlands

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:38

Gene therapy: A promising approach for hereditary haemoglobinopathies

Presented By

Dr Haydar Frangoul, Sarah Cannon Research Institute, USA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:32

Acquired TTP: new treatments and updated guidelines

Presented By

Dr María Mingot-Castellano, Hospital Universitario Virgen del Rocío, Spain

Trial

HERCULES; TITAN

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:25

Maternal screening to prevent foetal and neonatal alloimmune thrombocytopenia

Presented By

Prof. Dick Oepkes, Leiden University Medical Centre, the Netherlands

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:21

Fostamatinib effectively increased platelet counts in immune thrombocytopenic purpura

Presented By

Prof. Waleed Ghanima, University of Oslo, Norway

Trial

Phase 3, FIT-1,-2,-3

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:16

Physiopathology of coagulopathy in haematological malignancies and COVID-19

Presented By

Prof. Marcel Levi, Amsterdam University Medical Centre, the Netherlands

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:11

Haemostatic abnormalities are associated with mortality in COVID-19

Presented By

Dr Yu Hu, Wuhan Union Hospital, China

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:07

Mechanisms of COVID-19 vaccine-induced thrombotic thrombocytopenia

Presented By

Prof. Andreas Greinacher, Universitätsmedizin Greifswald, Germany

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:03

COVID-19 vaccine-induced immune thrombotic thrombocytopenia: discovery and diagnosis

Presented By

Prof. Sabine Eichinger, Medical University Hospital of Vienna, Austria

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:58

Novel targets in myelofibrosis: overview of emergent therapies

Presented By

Prof. Francesco Passamonti, University of Insubria, Italy

Trial

PERSIST; SIMPLIFY; BOREAS

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:54

Immune therapy of multiple myeloma

Presented By

Prof. Noopur Raje, Massachusetts General Cancer Center, USA

Trial

KarMMA; CARTITUDE-1; UNIVERSAL

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:49

MAIA results confirm superior efficacy of daratumumab with standard-of-care

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, MAIA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:46

ANDROMEDA: Addition of daratumumab showed superior efficacy in patients with AL amyloidosis

Presented By

Prof. Efstathios Kastritis, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, ANDROMEDA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:31

Sabatolimab achieved durable responses in patients with high-risk MDS and AML

Presented By

Prof. Andrew Wei, Alfred Hospital and Monash University, Australia

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:27

Final analysis of EURO-SKI: primary endpoints met in chronic myeloid leukaemia

Presented By

Prof. Susanne Saußele, Heidelberg University, Germany

Trial

EURO-SKI

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:13

Favourable outcomes with zanubrutinib versus ibrutinib in patients with r/r CLL

Presented By

Prof. Peter Hillmen, University of Leeds, UK

Trial

Phase 3, ALPINE

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:08

Oral azacitidine improves overall survival in patients with acute myeloid leukaemia

Presented By

Prof. Hartmut Döhner, Universitätsklinikum Ulm, Germany

Trial

Phase 2, QUAZAR AML-001

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:59

Reduced-intensity conditioning ASCT is effective in older patients with AML

Presented By

Prof. Nigel Russell, Guy's Hospital, UK

Trial

AML16; AML18

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:55

ELEVATE-TN: Acalabrutinib shows long-term efficacy in chronic lymphocytic leukaemia

Presented By

Dr Jeff Sharman, US Oncology Network, USA

Trial

Phase 3, ELEVATE-TN

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:50

ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety versus ibrutinib

Presented By

Prof. Peter Hillmen, St James’s University Hospital, UK

Trial

Phase 3, ELEVATE-RR

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:43

Fixed 12 cycles and MRD-guided venetoclax consolidation effective in CLL

Presented By

Dr Mark-David Levin, Albert Schweitzer Hospital, the Netherlands

Trial

Phase 2, HOVON 139/GiVe

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:38

GLOW: Ibrutinib + venetoclax showed superior PFS as first-line CLL treatment

Presented By

Prof. Arnon Kater, Amsterdam University Medical Centres, the Netherlands

Trial

Phase 2, GLOW

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:33

Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma

Presented By

Dr Marc André, Centre Hospitalier Universitaire UCL Namur, Belgium

Trial

CheckMate 205; KEYNOTE-087

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 12:26

MATRix with ASCT: best long-term survival for primary CNS lymphoma

Presented By

Dr Gerald Illerhaus, Klinikum der Landeshauptstadt Stuttgart, Germany

Trial

Phase 2, IELSG32

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 12:05

Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

Presented By

Dr Moshe Yair Levy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, USA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 11:55

The journey ahead for CAR T-cell therapy in r/r follicular lymphoma

Presented By

Dr Bastian von Tresckow, University Hospital Essen, Germany

Trial

ZUMA-5; ELARA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 11:47

ZUMA-5 vs SCHOLAR-5: Axicabtagene ciloleucel significantly improves FL outcome

Presented By

Prof. John Gribben, Barts Cancer Institute, UK

Trial

ZUMA-5; SCHOLAR-5

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 11:18

Promising chemo-free treatment options in r/r DLBCL

Presented By

Prof. Marco Ladetto, University del Piemonte Orientale, Italy

Trial

LOTIS-2

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 11:17

EHA 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

EHA 2021

1 July 2021 13:58

GLOW: Ibrutinib plus venetoclax showed superior efficacy as first-line treatment of CLL

Presented By

Prof. Arnon Kater, Amsterdam University Medical Centre, the Netherlands

Trial

Phase 3, GLOW

Conference

EHA 2021

16 June 2021 11:18

The discovery and diagnosis of COVID-19 vaccine-induced immune thrombotic thrombocytopenia

Presented By

Prof. Sabine Eichinger, Medical University Hospital of Vienna, Austria

Conference

EHA 2021

16 June 2021 11:06

Fixed 12 cycles and MRD-guided venetoclax consolidation is highly effective in CLL

Presented By

Dr Mark-David Levin, Albert Schweitzer Hospital, the Netherlands

Trial

Phase 2, HOVON 139/GiVe

Conference

EHA 2021

16 June 2021 10:52

ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety compared with ibrutinib

Presented By

Prof. Peter Hillmen, St James’s University Hospital, UK

Trial

Phase 3, ELEVATE-RR

Conference

EHA 2021

16 June 2021 09:50

Naratuximab emtansine plus rituximab is safe and effective in diffuse large B-cell lymphoma

Presented By

Dr Moshe Yair Levy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US

Trial

Phase 2

Conference

EHA 2021

16 June 2021 09:25

ASH 2020

Letter from the Editor

Editor

Prof. Gert Ossenkoppele, Amsterdam UMC, the Netherlands

Conference

ASH 2020

22 February 2021 11:58

Validation of MY-RADS response assessment category criteria

Presented By

Dr Angelo Belotti, ASST Spedali Civili di Brescia, Italy

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:43

High symptom burden in transplant-ineligible patients with newly diagnosed MM

Presented By

Dr Hira Mian, McMaster University, Canada

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:42

Added value of ixazomib to lenalidomide plus dexamethasone in transplant-ineligible newly diagnosed MM

Presented By

Prof. Thierry Facon, University Hospital Lille, France

Trial

Phase 3, TOURMALINE-MM2

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:37

Survival of transplant-eligible newly diagnosed MM in FORTE trial

Presented By

Dr Francesca Gay, GIMEMA, European Myeloma Network, Italy

Trial

Phase 2, FORTE

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:35

Better survival with upfront autoSCT versus bortezomib-based intensification

Presented By

Prof. Michele Cavo, University of Bologna, Italy

Trial

Phase 3, EMN02/HO95

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:29

Subcutaneous daratumumab plus pomalidomide and dexamethasone in R/R MM

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, APOLLO

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:26

Melflufen well tolerated with encouraging activity in heavily pretreated R/R MM

Presented By

Dr Enrique Ocio, University Hospital Marqués de Valdecilla, Spain

Trial

Phase 1/2, ANCHOR (OP-104)

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:22

Initial data of FcRH5/CD3 T-cell-engaging bispecific antibody

Presented By

Dr Adam Cohen, University of Pennsylvania, Philadelphia, USA

Trial

Phase 1, GO39775

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:20

Deep and durable responses with ide-cel in RRMM

Presented By

Dr Yi Lin, Mayo Clinic, Minnesota, USA

Trial

Phase 1, CRB-401

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:17

CD58 aberrations limit durable responses to CD19 CAR T-cell therapy

Presented By

Dr Robbie Majzner, Stanford University, California, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:15

Anti-CD19 CAR T-cell therapy in relapsed/refractory indolent NHL

Presented By

Dr Caron Jacobson, Dana Farber Cancer Institute, Massachusetts, USA

Trial

Phase 2, ZUMA-5

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:12

MPN disease burden, quality of life, and treatment patterns

Presented By

Dr Rami S. Komrokji (H. Lee Moffitt Cancer Center and Research Institute, Florida, USA) & Dr Michael R. Grunwald (Levine Cancer Institute, North Carolina, USA)

Trial

MOST

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:08

Interventions in JAK/STAT signalling pathway

Presented By

Dr Srdan Verstovsek, MD Anderson Cancer Center, Texas, USA

Trial

SIMPLIFY

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:05

Novel, orally available inhibitor of BCL-XL/BCL-2

Presented By

Dr Naveen Pemmaraju, MD Anderson Cancer Center, Texas, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:59

New insights into genetics of MPN

Presented By

Dr Jyoti Nangalia, University of Cambridge, United Kingdom

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:53

Mycophenolate efficacious and tolerable, even in elderly patients

Presented By

Dr Charlotte Bradbury, University of Bristol, United Kingdom

Trial

FLIGHT

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:50

First-in-class antibody sutimlimab selectively inhibits classical complement pathway

Presented By

Dr Catherine Broome, MedStar Georgetown University Hospital, Washington DC, USA

Trial

Phase 1

Conference

ASH 2020

18 February 2021 09:46

BTK inhibition provides clinically active and durable platelet response

Presented By

Dr David J. Kuter, Massachusetts General Hospital & Harvard Medical School, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:42

More complicated course of COVID-19 in leukaemia patients

Presented By

Dr Susanne Ghandili, University Medical Center Hamburg-Eppendorf, Germany

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:34

Older age and imatinib treatment associated with COVID-19 mortality in CML

Presented By

Dr Delphine Rea, Université de Paris, France

Trial

CANDID

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:32

Allogeneic SARS-CoV-2-specific T cells to treat COVID-19

Presented By

Dr Spyridoula Vasileiou, Baylor College of Medicine, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:30

More severe COVID-19 outcomes for patients with haematologic malignancies

Presented By

Prof. William A. Wood, University of North Carolina, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:28

Improved outcomes, but still substantial part experiences relapses

Presented By

Dr Danielle Fredman, Sheba Medical Center, Israel

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:26

Strong correlation between peripheral blood and bone marrow NGS MRD

Presented By

Dr Lori Muffly, Stanford University, California, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:24

Encouraging outcomes after autoHCT in patients with ALL

Presented By

Prof. Sebastian Giebel, Maria Skłodowska-Curie National Research Institute of Oncology, Poland

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:23

Prognostic validity of AML composite model in predicting mortality

Presented By

Dr Shannon Murphy, Dalhousie University, Canada

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:21

Venetoclax plus hypomethylating agents in favourable-risk AML

Presented By

Dr Shukaib Arslan, City Of Hope Helford Clinical Research Hospital, California, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:19

Encouraging clinical activity of decitabine plus ipilimumab in R/R or secondary MDS/AML

Presented By

Ms Jacqueline S. Garcia, Dana-Farber Institute, Massachusetts, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:18

Bosutinib effective and well tolerated in newly diagnosed CP-CML

Presented By

Prof. Tim Brümmendorf, RWTH Aachen University, Germany

Trial

Phase 3, BFORE

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:17

AML patients with specific mutations are unlikely to achieve MRD

Presented By

Dr Maximilian Stahl, Memorial Sloan Kettering Cancer Center, New York, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:15

Comparable outcomes with gilteritinib or quizartinib in R/R AML

Presented By

Dr Alexander Perl, University of Pennsylvania, USA

Trial

Phase 3, QuANTUM-R

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:14

First-in-class macrophage immune checkpoint inhibitor in AML

Presented By

Dr David Sallman, H. Lee Moffitt Cancer Center and Research Institute, Florida, USA

Trial

Phase 1

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:11

Bispecific DART® as salvage therapy for primary induction failure and early relapse

Presented By

Dr Ibrahim Aldoss, City of Hope Medical Center, California, USA

Trial

Phase 1/2

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:09

Efficacy and safety of ponatinib in patients with CP-CML who failed second-generation TKIs

Presented By

Dr Hagop Kantarjian, MD Anderson Cancer Center, Texas, USA

Trial

OPTIC, PACE

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:08

Gilteritinib in R/R AML patients priorly treated with midostaurin or sorafenib

Presented By

Dr Alexander Perl, University of Pennsylvania, USA

Trial

CHRYSALIS, ADMIRAL

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:07

Addition of venetoclax provides an effective, lower-intensity regimen

Presented By

Dr Tapan Kadia, MD Anderson Cancer Center, Texas, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:05

First-in-class STAMP inhibitor versus bosutinib in resistant or intolerant CML

Presented By

Dr Andreas Hochhaus, Universitätsklinikum Jena, Germany

Trial

Phase 3, ASCEMBL

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 08:58

PFS and ORR benefits of first-line ibrutinib-based treatment in CLL

Presented By

Prof. Jan Burger, MD Anderson Cancer Center, Texas, USA

Trial

Phase 3, RESONATE-2, iLLUMINATE

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 08:54

First results from gene therapy trial in haemophilia B

Presented By

Prof. Steven Pipe, University of Michigan, USA

Trial

Phase 3, HOPE-B

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 08:25

Impact of haemophilia on children and their caregivers

Presented By

Dr Kate Khair, Great Ormond Street Hospital for Children, UK

Trial

CHESS Paediatrics

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 08:22

Promising CRISPR gene editing results in β-thalassaemia and sickle cell disease

Presented By

Dr Haydar Frangoul, Sarah Cannon Research Institute, USA

Trial

CLIMB THAL-111 & CLIMB SCD-121

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 08:18

Erythroid maturation agent in patients with β-thalassaemia requiring regular RBC transfusions

Presented By

Prof. Olivier Hermine, Université de Paris, France

Trial

Phase 3, BELIEVE

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 08:12

ASH 2020 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASH 2020

9 December 2020 14:44

EHA 2020

EHA25 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

EHA 2020

9 September 2020 14:29

Letter from the Editor

Editor

Prof. Gert Ossenkoppele, Amsterdam UMC, the Netherlands

Conference

EHA 2020

9 September 2020 14:12

VIALE-A: newly diagnosed chemo-ineligible AML

Presented By

Dr Courtney Di Nardo, MD Anderson Cancer Centre, USA

Trial

Phase 3, VIALE-A

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 13:25

OS benefit in VIALE-C trial

Presented By

Prof. Andrew Wei, Monash University, Australia

Trial

Phase 3, VIALE-C

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 13:22

DEC10-VEN superior to intensive chemotherapy in high-risk AML

Presented By

Dr Abhishek Maiti, University of Texas MD Anderson Cancer Centre, USA

Trial

Phase 2

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 13:18

Magrolimab plus azacitidine: good ORR in MDS/AML

Presented By

Prof. Naval Draver, University of Texas MD Anderson Cancer Centre, USA

Trial

Phase 1

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 13:14

Asciminib monotherapy in Ph+ CML: major molecular responses

Presented By

Prof. Timothy Hughes, University of Adelaide, Australia

Trial

Phase 1

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 13:08

CML TKI interruption: Swedish registry results

Presented By

Dr Hjalmar Flygt, Uppsala University Hospital, Sweden

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 13:03

Patients with lower-risk MDS benefit from imetelstat

Presented By

Prof. Uwe Platzbecker, University Clinic Leipzig, Germany

Trial

Phase 2, IMerge

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:59

Better outcomes adding enasidenib to azacitidine in mIDH2-AML

Presented By

Dr Courtney Di Nardo, MD Anderson Cancer Centre, USA

Trial

Phase 2, AG-221-AML-005

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:55

PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma

Presented By

Dr Peter Borchmann, University Hospital of Cologne, Germany

Trial

Phase 3, HD17

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:51

Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma

Presented By

Prof. Pier Luigi Zinzani, University of Bologna, Italy

Trial

Phase 3, KEYNOTE-204

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:38

Promising first-in-human trial of epcoritamab in B-NHL

Presented By

Dr Martin Hutchings, Copenhagen University Hospital, Denmark

Trial

Phase 1/2, GEN3013

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:30

Two trials: acalabrutinib in CLL

Presented By

Prof. John Byrd, Ohio State University Comprehensive Cancer Centre, USA

Trial

Phase 2, ACE-CL-001, ASCEND

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:19

Zanubrutinib versus ibrutinib in Waldenström macroglobulinaemia

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, ASPEN

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:10

Deep responses in R/R CLL with venetoclax monotherapy

Expert

Prof. Arnon Kater, Amsterdam University Medical Center, the Netherlands

Trial

Phase 3, VENICE 1

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 11:35

MRD assessment post-CAR-T predicts ALL allo-HSCT bridging

Expert

Dr Hui Wang, Hebei Yanda Ludaopei Hospital, China

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 11:02

Daratumumab for light-chain amyloidosis

Presented By

Dr Efstathios Kastritis, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, ANDROMEDA

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 10:49

Isatuximab triplet improves PFS in R/R MM

Presented By

Prof. Philippe Moreau, University Hospital of Nantes, France

Trial

Phase 3, IKEMA

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 10:26

Initial results from CAR-T cell therapy in MM: KarMMa

Presented By

Prof. Jesús San Miguel, University of Navarra, Spain

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 10:19

GRAVITAS-301: improved complete aGVDH response

Presented By

Prof. Robert Zeiser, University Hospital Freiburg, Germany

Trial

Phase 3, GRAVITAS-301

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 10:02

Ruxolitinib improves steroid-refractory aGVHD across subtypes

Presented By

Prof. Robert Zeiser, University Hospital Freiburg, Germany

Trial

Phase 3, REACH2

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 09:57

Endothelial damage in COVID-19

Presented By

Dr George Goshua, Yale University, USA

Conference

EHA 2020

Type

Peer-reviewed article

28 August 2020 15:54

Paroxysmal nocturnal haemoglobinuria treatment with pegcetacoplan

Presented By

Prof. Peter Hillmen, St James's University Hospital, UK

Trial

Phase 3, PEGASUS trial

Conference

EHA 2020

Type

Peer-reviewed article

28 August 2020 15:53

Mitapivat, a pyruvate kinase-R activator, in SCD is safe with early efficacy results

Presented By

Dr Kevin HM Kuo, Princess Margaret Cancer Centre, Canada

Trial

Phase 1

Conference

EHA 2020

Type

Peer-reviewed article

28 August 2020 15:46

SCD LentiGlobin gene therapy: new data on VOC and ACS

Presented By

Dr Julie Kanter, University of Alabama, USA

Trial

HGB-206 Group C study

Conference

EHA 2020

Type

Peer-reviewed article

28 August 2020 12:37

Venetoclax + navitoclax promising for R/R ALL or LL

Presented By

Prof. Elias Jabbour , University of Texas MS Anderson Cancer Centre, USA

Trial

Phase 1

Conference

EHA 2020

Type

Peer-reviewed article

28 August 2020 12:23

Microbiome predicts B-ALL predisposition

Presented By

Dr Carolina Vincente-Dueñas, Institute of Biomedical Research of Salamanca, Spain

Conference

EHA 2020

Type

Peer-reviewed article

28 August 2020 12:15

Netrin-1 regulates haematopoietic stem cells

Presented By

Dr Simon Renders, German Cancer Research Centre, Germany

Conference

EHA 2020

Type

Peer-reviewed article

28 August 2020 12:12

Nivolumab/brentuximab vedotin in R/R HL: good CMR rates

Presented By

Prof. Christine Mauz-Körholz, Justus-Liebig-Universität Gießen, Germany

Trial

Phase 2, Checkmate 744

Conference

EHA 2020

Type

Peer-reviewed article

28 August 2020 12:09

Unrecognised role of iron in neutrophil differentiation

Presented By

Dr Bruno Galy, German Cancer Research Centre, Germany

Conference

EHA 2020

Type

Peer-reviewed article

28 August 2020 12:08

ASH 2019

Socioeconomic disparities and survival in paediatric AML

Presented By

Dr Lena Winestone, UCSF Benioff Children’s Hospital, USA

Trial

Phase 3, AAML0531 and AAML1031

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 23:55

HOVON-96: Better outcomes with cyclophosphamide after transplantation

Presented By

Dr Annoek Broers, Erasmus MC Cancer Institute, the Netherlands

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 23:53

Likely new standard of care: Blinatumomab for children with relapsed B-ALL

Presented By

Prof. Patrick A. Brown, Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Trial

Phase 3, AALL1331

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 23:15

Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma

Presented By

Dr Christine Chen, Princess Margaret Cancer Centre, University of Toronto, Canada

Trial

MM-003, STOMP

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 22:59

Erythroferrone and skeletal changes associated with thalassaemia

Presented By

Dr Melanie Castro-Mollo, Icahn School of Medicine at Mount Sinai, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 22:39

Pivotal phase 3 trial in cold agglutinin disease: sutimlimab can stop haemolysis

Presented By

Dr Alexander Röth, University of Duisburg-Essen, Germany

Trial

Phase 3, CARDINAL

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 22:36

Oral azacitidine improves overall survival in patients with AML in remission

Presented By

Dr Andrew Wei, Alfred Hospital, Australia

Trial

Phase 3, QUAZAR AML-001

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 21:39

CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients

Presented By

Dr Karl Kilgore, Avalere, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 21:07

BCL11A as a novel target in gene therapy for sickle cell disease

Presented By

Dr David Williams, Boston Children’s Hospital, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 20:45

BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM

Presented By

Dr Deepu Madduri, Mount Sinai Medical Center, USA

Trial

Phase 1/2, CARTITUDE-1

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 20:29

Rivaroxaban is safe and effective for paediatric venous thromboembolism

Presented By

Prof. Guy Young, Children's Hospital Los Angeles, USA

Trial

Phase 3, EINSTEIN-Jr

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 20:19

Arginine supplements help against sickle cell disease pain

Presented By

Prof. Richard Onalo, University of Abuja, Nigeria

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 20:18

Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM

Presented By

Prof. Saad Usmani, UNC-Chapel Hill School of Medicine, USA

Trial

Phase 3, CANDOR

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 19:49

Aspirin plus DOAC is not better than a DOAC alone

Presented By

Prof. Jordan Schaefer, University of Michigan, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 19:23

Mild renal impairment in African Americans does not affect OS in AML

Presented By

Dr Abby Statler, Cleveland Clinic, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 19:10

Long-term data of ropeginterferon alpha-2b in polycythaemia vera

Presented By

Prof. Jean-Jacques Kiladjian, Saint Louis Hospital, France

Trial

PROUD-PV

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 18:53

Anti-CD70 is safe with hypomethylating agents in AML

Presented By

Prof. Adrian Ochsenbein, Bern University Hospital, Switzerland

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 17:01

Anti-BCMA/anti-CD38 in refractory multiple myeloma

Presented By

Prof. Yu Hu, Huazhong University of Science and Technology, China

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 16:31

20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon

Presented By

Dr Maria Vazquez, MD Anderson Cancer Center, Houston, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 16:26

ALCYONE: New overall survival results for myeloma

Presented By

Dr Maria Victoria Mateos, University Hospital of Salamanca, Spain

Trial

Phase 3, ALCYONE

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 16:16

MRD assessment to guide pre-emptive treatment decisions

Presented By

Prof. Uwe Platzbecker, University Hospital Carl Gustav Carus, Germany

Trial

Phase 2, RELAZA2

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 16:04

Gene editing in congenital neutropenia

Presented By

Dr Shuquan Rao, Harvard Medical School, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 15:43

Abatacept prevents graft-versus-host disease in sickle cell patients after alloSCT

Presented By

Dr Niketa Shah, Yale University, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 15:20

Luspatercept effective for myelofibrosis-associated anaemia

Presented By

Prof. Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 15:11

Experimental model for limitations of haematopoietic stem cells propagation

Presented By

Dr Jennifer Myers SanMiguel, The Jackson Laboratory, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 14:47

Letter from the Editor

Editor

Prof. Gert Ossenkoppele, VU University Medical Center, the Netherlands

Conference

ASH 2019

5 March 2020 14:27

Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance

Presented By

Prof. Gill Singh, University of Hong Kong, China

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 14:13

Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT

Presented By

Dr Xiaowen Tang; Dr James Foran

Trial

Phase 2, ECOG-ACRIN E2906

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 13:16

Mosunetuzumab: complete remissions in non-Hodgkin lymphoma

Presented By

Prof. Stephen Schuster, University of Pennsylvania, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 09:50

Off-the-shelf natural killer cells

Presented By

Dr Jode Goodridge, Fate Therapeutics, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 09:38

EHA 2019

New sickle cell drug voxelotor boosts levels of haemoglobin

Presented By

Dr Jo Howard, King’s College London, United Kingdom

Trial

Phase 3, HOPE

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 23:49

CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma

Presented By

Prof. Phillippe Moreau, University Hospital of Nantes, France

Trial

Phase 3, CASSIOPEIA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 23:30

Introduction to the Conference Report of the EHA

Conference

EHA 2019

9 August 2019 23:23

Residual disease in AML patients prior to stem cell transplant increases relapse risk

Presented By

Dr Christopher Hourigan, NIH, USA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 23:05

Transformation of foetal haematopoietic stem and progenitor cells in the background of trisomy 21

Presented By

Dr Sophia Gialesaki, Hannover Medical School, Germany

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 23:00

Positive initial data evaluating the safety and efficacy of IMR-687 for treatment of sickle cell disease

Presented By

Dr Biree Andemariam, UConn Health, USA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 22:50

Unmutated IGHV as predictive factor for venetoclax/obinutuzumab benefit in frontline CLL

Presented By

Dr Eugen Tausch, University of Ulm, Germany

Trial

CLL14

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 22:38

Chimeric antigen receptor T cell therapy in multiple myeloma

Presented By

Prof. Hermann Einsele, University of Würzburg, Germany

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 22:34

Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML

Presented By

Dr Alexander Perl, University of Pennsylvania, USA

Trial

Phase 3, ADMIRAL

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 22:14

Treating thalassemia twice, in mice

Presented By

Dr Antonella Nai, San Raffaele Scientific Institute, Italy

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 22:03

Haematopoietic stem cell transplantation improves stroke risk in children with sickle cell anaemia

Presented By

Dr Francoise Bernaudin, Intercommunal Hospital Center de Créteil, France

Trial

DREPAGREFFE

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 21:52

CAR-T cell therapy in ALL as breakthrough advance

Presented By

Prof. Mohamad Mohty, Saint-Antoine Hospital and University Pierre & Marie Curie, France

Trial

Phase 2, ELIANA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 21:36

Higher levels of treatment satisfaction without compromising efficacy: subcutaneous daratumumab in RRMM

Presented By

Prof. María-Victoria Mateos , University of Salamanca, Spain

Trial

Phase 3, COLUMBA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 21:36

Initial data on AMV564 in patients with relapsed/refractory AML

Presented By

Prof. Gail Roboz, Weill Cornell Medicine, USA

Trial

Phase 1, AMV564-101

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 21:18

Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma

Presented By

Dr Steven Horwitz , Memorial Sloan Kettering Cancer Center, USA

Trial

Phase 3, ECHELON-1

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 20:49

Adding isatuximab to pomalidomide and dexamethasone improves PFS and ORR in RRMM

Presented By

Prof. Michel Attal, University Institute Cancer Toulouse Oncopole, France

Trial

Phase 3, ICARIA-MM

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 20:38

Overcoming the “don’t eat me” signal in AML and MDS

Presented By

Dr David Sallman, Moffitt Cancer Center, USA

Trial

5F9005

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 20:20

Haematopoietic stem cells can sense tissue damage in the gut

Presented By

Dr Hitoshi Takizawa, Kumamoto University, Japan

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 20:19

Infectious complications mild and not common in patients receiving CAR-T therapy for diffuse large B cell lymphoma

Presented By

Dr Roberta Di Blasi, Hospital Saint-Louis, France

Trial

JULIET and ZUMA1

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 19:55

Early trial data shows positive results for treating anaemia in patients with end-stage renal failure

Presented By

Prof. Lutz Renders, Klinikum Rechts der Isar, Germany

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 19:54

Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed amyloid light chain amyloidosis

Presented By

Prof. Raymond Comenzo, Tufts University, USA

Trial

Phase 3, ANDROMEDA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 19:40

Obinutuzumab/polatuzumab in follicular lymphoma

Presented By

Prof. Wojciech Jurczak, Jagiellonian University, Poland

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 17:13

Exciting survival data for ibrutinib vs placebo in treatment-naïve, early-stage CLL

Presented By

Dr Petra Langerbeins, University of Cologne, Germany

Trial

Phase 3, CLL12

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 16:26

ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL

Presented By

Dr Paolo Ghia, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, ASCEND

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 15:28

Asciminib plus imatinib in patients with heavily pre-treated chronic myeloid leukaemia

Presented By

Prof. Jorge Cortes, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 1

Conference

EHA 2020

Type

Peer-reviewed article

9 August 2019 12:22

Editor Biography

Editor

Prof. Gert Ossenkoppele, VU University Medical Center, Amsterdam, the Netherlands

Conference

EHA 2019

9 August 2019 11:53

Interview with EHA President Prof. Pieter Sonneveld

Expert

Prof. Pieter Sonneveld, Erasmus Medical Center in Rotterdam, the Netherlands

Conference

EHA 2019

9 August 2019 09:59

Venetoclax for multiple myeloma: effective but some safety concerns

Presented By

Dr Shaji Kumar, Mayo Clinic, USA

Trial

Phase 3, BELLINI

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 09:42

Guadecitabine vs treatment of choice in AML

Presented By

Prof. Pierre Fenaux, Hôpital Saint-Louis, France

Trial

Phase 3, ASTRAL-1

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 09:25

Promising news for gene therapy for sickle cell disease

Presented By

Dr Olivier Hermine, Necker Hospital, France

Trial

Phase 1/2, HGB-206

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 08:25

Venetoclax-obinutuzumab combination elicits high response rates in CLL

Presented By

Dr Kirsten Fischer, University of Cologne, Germany

Trial

Phase 3, CLL14

Conference

EHA 2019

Type

Peer-reviewed article

9 June 2019 23:28